Gilead on Thursday reported revenue growth in the first quarter of 2024, driven by the strong sales of its HIV, cancer and ...

Evernorth Health Services will offer Humira biosimilar products with no out-of-pocket cost through its Accredo specialty ...

Is there a connection between Bristol Myers Squibb’s announcement that it will reduce its headcount by 6% and the company’s ...

With its lawsuit filed against Pfizer and BioNTech, the British multinational biopharma has joined the high-profile patent ...

The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the ...

A report from the Kaiser Family Foundation estimates that the FDA’s recent approval of Novo Nordisk’s Wegovy to reduce the ...

Regeneron will use Mammoth Biosciences’ tiny Cas enzymes to deliver in vivo CRISPR-based gene editing therapies to tissues ...

Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved ...

Sanofi is dropping its Sjögren’s syndrome candidate due to disappointing Phase II efficacy data, while AstraZeneca is ...

Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to ...

Xaira Therapeutics emerged from stealth on Wednesday with plans to tap the biological equivalent of artificial intelligence ...

The FTC’s final rule banning most new noncompetes should go into effect later this year, although it faces opposition from ...